Dual-Target CAR-T Therapy Shows High Efficacy in Myeloma Trial

The trial, led by Professor Jin Lu of Peking University People's Hospital, focused on patients who had exhausted multiple prior lines of treatment. Participants received a single infusion of RD140, a fully human CAR-T therapy designed to target both BCMA and GPRC5D proteins. Among the cohort, which included patients with plasma cell leukemia and extramedullary disease, the higher-dose group recorded a 100% objective response rate. Researchers noted that 88.9% of participants reached minimal residual disease negativity by the May 2026 data cutoff.

Safety profiles remained manageable throughout the study. While cytokine release syndrome was observed in all patients, cases were predominantly low-grade, and no instances of immune effector cell-associated neurotoxicity syndrome occurred. Beyond clinical outcomes, the platform relies on a rapid manufacturing process that prepares the therapeutic cells in three to four days. This turnaround time is critical for patients with aggressive malignancies who require immediate intervention. The median progression-free survival has not yet been reached, and investigators plan to expand the study to validate these initial findings across a larger population.